Profound Medical Corp. Share Price

Equities

PRN

CA74319B5027

Advanced Medical Equipment & Technology

Market Closed - Toronto S.E. 20:59:59 26/04/2024 BST 5-day change 1st Jan Change
10.84 CAD -3.73% Intraday chart for Profound Medical Corp. +5.76% -2.34%

Financials

Sales 2024 * 15.95M 11.66M 934M Sales 2025 * 43.69M 31.94M 2.56B Capitalization 265M 194M 15.51B
Net income 2024 * -38M -27.78M -2.23B Net income 2025 * -30M -21.93M -1.76B EV / Sales 2024 * 15.7 x
Net cash position 2024 * 13.74M 10.04M 804M Net Debt 2025 * 41.34M 30.22M 2.42B EV / Sales 2025 * 7.01 x
P/E ratio 2024 *
-6.95 x
P/E ratio 2025 *
-7.72 x
Employees 131
Yield 2024 *
-
Yield 2025 *
-
Free-Float 91.29%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Profound Medical Corp. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 11:15 AM
Alliance Global Partners Trims Price Target on Profound Medical to $10.80 From $12.75, Maintains Buy Rating MT
Stifel Adjusts Price Target on Profound Medical to $9 From $11, Keeps Hold Rating MT
Profound Medical Corp. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Transcript : Profound Medical Corp., Q4 2023 Earnings Call, Mar 07, 2024
Profound Medical Reports Q4 Net Loss of US$0.42 Per Share, Announces COO Appointment MT
Profound Medical Brief: Announcing promotion of Mathieu Burtnyk, from SVP Product Leader to Chief Operating Officer MT
Profound Medical Brief: Q4 2023 net loss was approximately US$8.9 million, or $0.42 per common share MT
North American Morning Briefing : Powell Still in the Spotlight; ECB Rate Decision Looms DJ
Profound Medical Collaborates With Siemens Healthineers to Expand Physician and Patient Access to the TULSA Procedure MT
Profound Medical Corp. Enters into A Non-Exclusive Collaboration with Siemens Healthineers CI
Profound Medical Brief: Entering Collaboration with Siemens Healthineers to Further Expand Physician and Patient Access to the TULSA Procedure MT
Profound Medical Up 1.9% In US After Hours As Announces Non-Brokered Private Placement MT
Profound Medical Corp. announced that it expects to receive $2.937503 million in funding CI
Profound Medical Brief: Adds Top priorities for 2024 will be to further increase Its TULSA-PRO installed base, support increased system utilization, complete its ongoing Level 1 CAPTAIN trial MT
More news
1 day-3.73%
1 week+5.76%
Current month-5.08%
1 month-2.43%
3 months-10.41%
6 months-8.45%
Current year-2.34%
More quotes
1 week
10.25
Extreme 10.25
11.34
1 month
10.15
Extreme 10.15
11.65
Current year
9.55
Extreme 9.55
12.72
1 year
9.55
Extreme 9.55
20.44
3 years
4.21
Extreme 4.21
25.00
5 years
4.21
Extreme 4.21
36.73
10 years
4.21
Extreme 4.21
36.73
More quotes
Managers TitleAgeSince
Chief Executive Officer 69 03/06/15
Director of Finance/CFO 56 30/06/15
Chief Operating Officer 42 06/07/11
Members of the board TitleAgeSince
Director/Board Member 77 13/06/18
Director/Board Member 67 13/06/18
Director/Board Member - 02/03/21
More insiders
Date Price Change Volume
26/04/24 10.84 -3.73% 3,688
25/04/24 11.26 +4.26% 5,850
24/04/24 10.8 +2.08% 2,915
23/04/24 10.58 +0.09% 1,100
22/04/24 10.57 +3.12% 4,389

Delayed Quote Toronto S.E., April 26, 2024 at 08:59 pm

More quotes
Profound Medical Corp. is a Canada-based commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue. It is commercializing TULSA-PRO, a technology that combines real-time magnetic resonance imaging (MRI), robotically driven transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum. TULSA-PRO has the potential to be a flexible technology in customizable prostate ablation, including intermediate stage cancer, localized radio-recurrent cancer, retention and hematuria palliation in locally advanced prostate cancer and the transition zone in large volume benign prostatic hyperplasia. It is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
10.84 CAD
Average target price
12.5 CAD
Spread / Average Target
+15.31%
Consensus